key: cord-0706113-g5u12kos
authors: Strugnell, Richard; Wang, Nancy
title: Sustained neutralising antibodies in the Wuhan population suggest durable protection against SARS-CoV-2
date: 2021-03-18
journal: Lancet
DOI: 10.1016/s0140-6736(21)00434-7
sha: 8b98cfa387aee843fa776550d9c2fef7dcf3ae66
doc_id: 706113
cord_uid: g5u12kos

nan

SARS-CoV-2 infections were first reported in Wuhan, China, in 2019, 1 and quickly became a global pandemic, as declared on March 11, 2020. 2 SARS-CoV-2 is highly infectious 3 and COVID-19 is variable in its presentation, with many infected individuals, as detected by viral nucleic acid screening, being asymptomatic.

In The Lancet, Zhenyu He and colleagues 4 report their cross-sectional study of serological responses of more than 9500 individuals from 3600 households in Wuhan, the early epicentre for the COVID-19 outbreak. The study was initiated shortly after lockdown in Wuhan ceased in April, 2020, with follow-up over two timepoints

See Articles page 1075 (June and October-December, 2020). In this cross-sectional, longitudinal serosurvey of Wuhan residents, the authors estimated the penetration of the virus into the community who were selected using a population-stratified, randomsampling approach. They also examined the development and durability of SARS-CoV-2 neutralising antibodies, the putative correlate of protection in COVID-19. 5 In the Wuhan population sampled by He and colleagues, 532 (5·6%) of 9542 participants were positive for pan-immunoglobulins against SARS-CoV-2 at baseline, giving an adjusted seroprevalence of 6·92% (higher than an earlier report, 6 which estimated a seroprevalence of 3·2-3·8%). More than 80% of those surveyed who were seropositive were asymptomatic. As a city of 11 million people with 9 million residents as estimated during lockdown, 6 quick extrapolation of these estimates suggests that approximately 622 800 individuals in Wuhan would have been infected as of April, 2020, far exceeding the cumulative number of confirmed cases in Wuhan (50 333 as of April 17, 2020 7 ). If the seroconversion rate is an accurate reflection of exposure to SARS-CoV-2, the apparent disparity between low case numbers and high seroconversion rate seems to suggest that most seroconverted individuals produced antibodies to SARS-CoV-2 after asymptomatic infection. Accordingly, by occupation group, the highest seroconversion rate was seen in health workers and in those with known COVID-19 contacts in the past 5 months. This observation suggests a relay of exposure that frequently resulted in asymptomatic transmission chains because, when the full population of Wuhan was screened in May, 2020, few additional, asymptomatic cases were detected compared with the known number of confirmed cases in April, 2020. 8 Although separating transmitting from non-transmitting asymptomatic individuals with COVID-19 is probably impractical, the transmission outcomes from these two patient cohorts would suggest that different management regimens might be considered.

He and colleagues detected neutralising antibodies in 39·8% of the seropositive subgroup; encouragingly, the proportion was sustained over the 9-month study period, indicating that putative protection was durable when it occurred. Moreover, titres of neutralising antibodies were lower in individuals who had asymptomatic infections, compared with those with symptomatic infection and confirmed cases. The reason why those with asymptomatic disease developed lower neutralising antibody titres than those with symptomatic disease might be simply explained by different levels of exposure to SARS-CoV-2 antigens. Whether the levels of neutralising antibodies, or their transient appearance, also affected the so-called transmissibility potential would require further investigation.

Efficient global management of COVID-19 will probably succeed or fail on the basis of the immunity induced by natural infection and, especially, vaccination. Given the relative paucity of neutralising antibodies through natural infection, the study by He and colleagues reinforces the need for effective COVID-19 vaccines in the populationlevel control of the disease. The extraordinary, rapid, and effective control measures implemented in Wuhan might have restricted the spread of the virus, but also reduced naturally acquired herd immunity by truncating the development of sustained neutralising antibodies. Although other national and local governments have used alternate and usually less effective strategies to control the spread of SARS-CoV-2, even in highly endemic communities the prevalence of disease is usually less 1%, but has increased to 23% in some communities. [9] [10] [11] [12] He and colleagues' findings suggest that herd immunity will likely not develop after natural transmission in settings where infection control mechanisms are successfully introduced, underscoring the importance of effective vaccination strategies to control the spread of COVID-19.

This study is an important milestone in the description of SARS-CoV-2 infection and our understanding of immunity in the pandemic. He and colleagues have provided a much deeper understanding of natural seroconversion in a key city in the pandemic and their findings also underscore the remarkable achievement of the Chinese public health system in controlling the Wuhan outbreak of COVID-19 at a time when testing, tracing, and treatment resources were much less developed. Improved identification and interventions against the standard modifiable cardiovascular risk factors (SMuRFs; hypertension, diabetes, hypercholesterolaemia, and smoking) have contributed to reduced risk of cardiovascular events and death among patients with ST-elevation myocardial infarction (STEMI). 1 However, the proportion of patients who present with STEMI without SMuRFs (termed SMuRF-less) is increasing and accounts for 15-30% of patients with STEMI. 2,3 In The Lancet, Gemma Figtree and colleagues 4 report on data from the Swedish healthcare registry on heart disease, SWEDEHEART and SMuRF-less patients had worse left ventricular function and higher concentrations of troponins, but lower prescription rates of recommended treatments (angiotensin converting enzyme inhibitors or angiotensin receptor blockade and β-blockers) at discharge, compared with their counterparts with at least one SMuRF. As such, optimisation of risk assessment and treatment in SMuRFless patients is needed to improve prognosis in this growing subgroup of patients presenting with STEMI.

In general, major sex differences exist in the prevalence and clustering of risk factors. In women, SMuRFs are more prevalent with clustering, particularly in postmenopausal women with STEMI. 5 Furthermore, absence of sex-specific cutoff values might underestimate the prevalence of risk factors in women. In addition, femalespecific cardiovascular risk factors including premature menopause, ovarian dysfunction, hormone therapy, and pregnancy complications with pre-eclampsia and gestational diabetes have been identified. 5 Psychosocial factors, rheumatic diseases, and autoimmune diseases have also been associated with increased cardiovascular risk in women. 5 Recommended clinical risk score models are often incomplete and unable to identify individuals at high risk of cardiovascular events, or underestimate risk, particularly in SMuRF-less patients and women. 6 These shortfalls limit the possibilities for both primary and secondary prevention in these patients. Despite evidence of associations between sex-specific risk factors and increased cardiovascular risk, such risk factors are often not accounted for in risk stratification. 6 Improved risk score models including new genetic, metabolic, and inflammatory biochemical biomarkers are warranted. 7 In addition, imaging biomarkers of subclinical cardiovascular disease, including cardiac remodelling, arterial stiffness and remodelling, coronary artery plaque burden, plaque vulnerability, and coronary perivascular inflammation, has been suggested to improve risk stratification. 8, 9 In a 2021 position paper from the European Society of Cardiology working group on the cellular biology of the heart, the importance of sex-specific differences in cardiovascular risk and the need for translational research to identify new risk markers in women were highlighted. 10 However, new risk score models should be clinically useful and evaluated in large populations. Reliable performance

COVID-19-neutralizing antibodies predict disease severity and survival

Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China

Epidemic situation of new COVID-19 in Hubei Province on

Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China

Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity

Seroprevalence of SARS-CoV-2-specific antibodies in Sydney after the first epidemic wave

SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study

Estimated SARS-CoV-2 seroprevalence in the US as of

We declare no competing interests.Richard Strugnell*, Nancy Wang rastru@unimelb.edu.au